Tiziana Life Sciences Ltd
intranasal foralumab
non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Countdown
87days
Phase 2 readout · Oct 1, 2026
What's at stake
Phase 2 trial results for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) are due Oct 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“will also to be presented at the 10 th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026.”